Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Eqrx Inc (EQRX)

Eqrx Inc (EQRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,140,551
  • Shares Outstanding, K 487,415
  • Annual Sales, $ 0 K
  • Annual Income, $ -169,090 K
  • 60-Month Beta 0.48
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.97
Trade EQRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.55
  • Most Recent Earnings $-0.15 on 08/08/23
  • Latest Earnings Date 11/09/23
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.18
  • Growth Rate Est. (year over year) +555,100.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.01 +16.42%
on 10/30/23
2.63 -10.86%
on 11/03/23
+0.12 (+5.41%)
since 10/06/23
3-Month
2.01 +16.42%
on 10/30/23
2.63 -10.86%
on 11/03/23
+0.10 (+4.46%)
since 08/08/23
52-Week
1.58 +48.10%
on 05/02/23
5.55 -57.84%
on 11/09/22
-3.22 (-57.91%)
since 11/08/22

Most Recent Stories

More News
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HCCI, EQRX, CFMS

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

HCCI : 45.51 (+0.09%)
EQRX : 2.34 (-2.09%)
CFMS : 2.26 (unch)
Shareholder Alert: Ademi LLP investigates whether EQRx, Inc. has obtained a Fair Price in its transaction with Revolution Medicines

/PRNewswire/ -- Ademi LLP is investigating EQRx (Nasdaq: EQRX) for possible breaches of fiduciary duty and other violations of law in its transaction with...

EQRX : 2.34 (-2.09%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RETA, EQRX, RVMD

/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...

RETA : 172.36 (+0.02%)
EQRX : 2.34 (-2.09%)
RVMD : 35.54 (-1.47%)
EQRx, Inc. (EQRX) Shareholder Investigation: Robbins LLP is Investigating EQRX, Inc. on behalf of Shareholders

Shareholder rights law firm Robbins LLP is investigating EQRx, Inc. (NASDAQ: EQRX) to determine whether certain EQRx officers and directors violated securities laws and breached fiduciary duties to shareholders....

EQRX : 2.34 (-2.09%)
Indaptus (INDP) Surges on Upbeat Pre-Clinical Decoy Data

Indaptus (INDP) announces positive pre-clinical efficacy data from a poster presentation made at a scientific conference from its proprietary Decoy platform pre-clinical study. Stock is up 22%.

RCEL : 9.46 (-4.25%)
INDP : 2.62 (-5.51%)
BTTX : 0.0099 (-16.81%)
EQRX : 2.34 (-2.09%)
Novo Nordisk (NVO) Increases Sales & Operating Profit Guidance

Novo Nordisk (NVO) increases annual guidance for the year 2023 on higher sales expectations for Ozempic and Wegovy.

NVO : 123.90 (-0.49%)
INVA : 14.40 (-1.57%)
RCEL : 9.46 (-4.25%)
EQRX : 2.34 (-2.09%)
Novo (NVO) & Aspect Biosystems Unite to Develop Tissue Therapy

Pharma Goliath Novo Nordisk (NVO) inks collaboration agreement with Aspect Biosystems to develop and commercialize transformative cell therapy treatments for type I diabetes patients.

NVO : 123.90 (-0.49%)
INVA : 14.40 (-1.57%)
RCEL : 9.46 (-4.25%)
EQRX : 2.34 (-2.09%)
Creative Medical (CELZ) Up 86% on Upbeat Diabetes Study Data

Creative Medical Technology (CELZ) reports positive one-year follow-up data from a study showing the efficacy of CELZ-001 in treating type II diabetes without any serious adverse effects.

CRSP : 58.72 (-3.21%)
CERT : 17.44 (-1.30%)
CELZ : 5.21 (unch)
EQRX : 2.34 (-2.09%)
Aurinia (AUPH) Up 11% on Issue of New Additional Lupkynis Patent

Aurinia Pharmaceuticals (AUPH) announces the issue of its new and refined method-of-use patent, supplementing its existing patent, for Lupkynis to treat lupus nephritis. Shares are up 11%.

AUPH : 5.04 (-1.18%)
RCEL : 9.46 (-4.25%)
BTTX : 0.0099 (-16.81%)
EQRX : 2.34 (-2.09%)
Moderna (MRNA) Posts 2027 Biz View, Down 3% on Flu Jab Setback

Moderna (MRNA) expects $8-$15 billion in product revenues from the respiratory vaccine by 2027. Its first influenza vaccine candidate failed to meet the statistical threshold for early success.

MRNA : 103.86 (-1.22%)
CRSP : 58.72 (-3.21%)
CERT : 17.44 (-1.30%)
EQRX : 2.34 (-2.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

EQRx Inc. is a pharmaceutical company is involved in developing and delivering medicines to patients. EQRx Inc., formerly known as CM Life Sciences III, is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 2.50
2nd Resistance Point 2.46
1st Resistance Point 2.40
Last Price 2.34
1st Support Level 2.30
2nd Support Level 2.26
3rd Support Level 2.20

See More

52-Week High 5.55
Fibonacci 61.8% 4.03
Fibonacci 50% 3.57
Fibonacci 38.2% 3.10
Last Price 2.34
52-Week Low 1.58

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar